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CXCL12 is a chemokine essential for the organ-speciﬁc spread of a variety of cancers including small
cell lung cancer (SCLC). Here, we examined the anti-metastatic efﬁcacy of TF14016, a small peptidic
inhibitor of CXCL12 receptor CXCR4, in SCLC. Treatment of mice with TF14016 signiﬁcantly
suppressed pulmonary metastases of CXCR4-expressing SCLC in size and number. Furthermore,
histological examination revealed that the expression of vascular endothelial cell growth factor
and the density of CD31-positive microvessels in metastatic foci were both signiﬁcantly reduced
in TF14016-treated mice. Collectively, CXCR4 could be an attractive target for anti-metastatic and
anti-angiogenic therapy in SCLC.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction have shown that CXCR4 play important roles in migration and or-Lung cancer is the leading cause of cancer-related deaths
worldwide. Approximately 15% of all histological types consist of
small cell lung cancer (SCLC) that is an aggressive malignancy with
extremely high mortality. Namely, SCLC cells metastasize micro-
scopically to systemic organs early in its clinical course. To escape
from chemotherapy-induced apoptosis, they utilize survival
signals from surrounding extra-cellular matrices via integrins as
well as from a variety of growth factor receptors and also express
drug efﬂux pumps. Thus, they easily acquire multidrug resistance
(MDR) [1]. Since no favorable therapeutic strategy has been
established for relapsed SCLC to date, new approaches are urgently
desired to overcome MDR of SCLC.
CXCR4 is a seven-transmembrane G protein-coupled chemo-
kine receptor for its natural ligand CXCL12 and is also known as
a coreceptor for human immunodeﬁciency virus [2]. We and otherschemical Societies. Published by E
rg-Nal-Cys-Tyr-Cit-Lys-D-Lys-
espiratory Medicine, Allergy
te School of Medicine, 2-2
6 6879 3839.
(T. Kijima).
the ﬁrst authors.gan-speciﬁc metastasis of SCLC cells which commonly express this
receptor [3–5]. Namely, stromal cells in the bone marrow and
lymph nodes, where SCLC cells preferentially metastasize, produce
considerable amounts of CXCL12 and the concentration gradient
between these organs and bloodstream causes organ-speciﬁc
metastases of SCLC. Therefore, deprivation of metastatic potential
from SCLC cells is an attractive therapeutic strategy. Methodologies
for targeting CXCR4 include neutralization by antibodies [6],
silencing by small interfering RNAs (siRNAs) [7], and functional
blocking by small molecule antagonists [8–10]. T140 analogs are
small peptidic CXCR4 antagonists composed of 14 amino acid res-
idues. Among them, TF14016 is the most potent and bio-stable
T140 analog [11]. We here investigated the therapeutic potential
of TF14016 in SCLC, focusing on adhesion, migration and motility
in vitro, and moreover on systemic metastases in vivo.
2. Materials and methods
2.1. Cell lines and cell culture
SCLC cell lines SBC-5 and NCI-H446 were purchased from
Japanese Collection of Research Bioresources (Ibaraki, Osaka,
Japan) and American Type Culture Collection (Rockville, MD),lsevier B.V. All rights reserved.
3640 Y. Otani et al. / FEBS Letters 586 (2012) 3639–3644respectively. Both cell lines express considerable amount of CXCR4
(Supplementary Fig. 1) and were maintained in RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
penicillin (100 units/ml), and streptomycin (100 lg/ml).
2.2. Reagents
TF14016 is the most potent and bio-stable peptide-based
CXCR4 antagonist as described previously [11]. Recombinant
human CXCL12 was purchased from PeproTech (Rocky Hill, NJ). Bo-
vine plasma ﬁbronectin was obtained from Sigma (St. Louis, MO).
2.3. Adhesion assay
Cellular adhesive potential was evaluated as mentioned in our
previous reports [3]. Brieﬂy, cells (1  105/well) were allowed to
adhere in the presence or absence of TF14016 (100 nmol/l) and
CXCL12 (100 ng/ml) for 2 h at 37 C. After removing unattached
cells by shaking and washing, the relative number of attached cells
was determined using Cell Counting Kit-8 following the instruction
manual (Dojindo Lab, Kumamoto, Japan).
2.4. Migration assay
Migration of SBC-5 cells was assayed using 24-well transwell
chambers with 8.0 lm pore ﬁlters (Coster, Boston, MA). Cells
(1  104/100 ll) were added to the upper chambers and then the
lower chambers were ﬁlled with 0.6 ml of RPMI 1640 containing
0.5 lg/ml bovine plasma ﬁbronectin and 1% FBS with or without
100 ng/ml CXCL12 and/or 100 nmol/l TF14016. The chambers were
incubated for 20 h at 37 C. The ﬁlters were ﬁxed and stained with
Diff-Quick reagent (Dade Behring, Dugen, Switzerland). The upper
surface of the ﬁlters was scraped twice with cotton swabs to re-
move non-migrating cells. The number of migrating cells was
counted by a microscope (HS BZ-9000, Keyence, Osaka, Japan)
using Dynamic Cell Count software (BZ-II Analyzer version 1.30,
Keyence).
2.5. Cell motility analysis by time-lapse video microscopy (TLVM)
Cells (1  105) in 5% FBS-containing media were plated in
35 mm dishes (Corning, Corning, NY) and allowed to adhere for
2 h. After TF14016 (100 nmol/l) and/or CXCL12 (100 ng/ml) were
added, dishes were placed into a temperature- and humidity-
controlled chamber (IX-IBM, Olympus, Tokyo, Japan). Cells were re-
corded for another 4 h by TLVM using an inverted microscope
(IX70, Olympus) equipped with a charge-coupled device camera
(Cool-Snap HQ cooled 12-bit, Roper Scientiﬁc, Trenton, NJ). Digital
video images were saved every 3 min and cellular movement was
analyzed with MetaMorph software (Universal Imaging Co. Ltd.,
Downingtown, PA) then plotted to show the trace of movement.
The mean distance that a cell traversed for each 3 min was also
calculated.
2.6. TF14016 treatment in experimental metastasis mouse model
Male severe combined immunodeﬁcient (SCID) C.B-17/Icr-scid/
scid Jcl mice, aged 6 weeks, were obtained from Clea (Osaka, Ja-
pan). Experiments were performed according to the guidelines
of our university. To facilitate the metastasis of SBC-5 cells, natu-
ral killer (NK) cells were depleted by the treatment with rabbit
anti-asialo GM1 antibody (Ab) (Wako), 200 lg of which was
administered intraperitoneally (i.p.) twice a week from 2 days be-
fore tumor cell inoculation to the end of the experiment. SBC-5
cells (2.5  106) in 300 ll phosphate buffered saline (PBS) wereinjected into the lateral tail veins of mice 1 h after the ﬁrst
TF14016 administration. Treatment by TF14016 (10 mg/kg i.p.)
was started on the day of tumor cell injection and continued daily.
After 12 weeks, mice were sacriﬁced. All major organs were exam-
ined for the presence of metastatic nodules in gloss and ﬁxed in
4% paraformalin then embedded in parafﬁn for microscopic
analysis.
2.7. Immunohistochemistry
Sections (4 lm thick) of formalin-ﬁxed and parafﬁn-embedded
tumors were subjected to immunostaining for CD31 and vascular
endothelial cell growth factor (VEGF) using immunoperoxidase
procedure. Antigen retrieval was done by proteinase K for CD31
but not for VEGF. After inactivation of endogenous peroxidase
and blockade of nonspeciﬁc reaction, immunoreaction was per-
formed overnight at 4 C with primary Abs, anti-mouse CD31
rat monoclonal Ab (diluted 1:10; BMA Biomedicals, Augst, Swit-
zerland) or anti-human VEGF mouse monoclonal Ab (diluted
1:500; Upstate, Temecula, CA). Sections were washed and subse-
quently incubated with secondary Abs, biotinylated anti-rat
immunoglobulin rabbit Ab (diluted 1:200; Dako, Tokyo, Japan)
or peroxidase-conjugated anti-mouse immunoglobulin goat Ab
(Nichirei, Tokyo, Japan), for 10–30 min at room temperature.
Biotin was labeled with peroxidase-conjugated streptavidin
(Dako) for 10 min at room temperature. Signals were visualized
by reaction with 3,30-diaminobenzidine-4HCl (Sigma) for 5 min
at room temperature and counterstained with Mayer’s hematoxy-
lin. Sections were also stained with H&E for routine histological
examination.
2.8. Assessment of microvessel density (MVD) and VEGF expression
MVD was evaluated using the counting method as described
previously [12]. Brieﬂy, 10 tumor foci with a great density of
CD31-positive endothelial cells were randomly selected from each
treated group. A linear formation, a cluster in cross-section, a
branch point per line, or a lumen formation of endothelial cells
was counted as one microvessel, respectively. The immunoreactiv-
ity of VEGF was evaluated by the portion of stained SCLC cells that
had an intermediate/strong semi-quantitative staining intensity
among all SCLC cells included in a nodule. The top 10 tumor foci
with high VEGF positivity were selected to the assessment from
each treated group.
2.9. Measurement of VEGF concentrations
Cells (3  104) were pre-incubated in 10% FBS-containing
media in each well of 48-well tissue culture-treated plates
(Sumitomo Bakelite, Tokyo, Japan) for 24 h. After replacement
to the fresh media, cells were incubated with or without CXCL12
(100 ng/ml) and/or TF14016 (100 nmol/l) for another 24 h either
in normoxic or hypoxic condition. For hypoxic condition, the cells
were incubated in a modular chamber ﬂushed with 1% O2, 5%
CO2 and 94% N2. Conditioned media were collected and subjected
to the enzyme-linked immunosorbent assay (ELISA) for VEGF
using Quantikine ELISA Kit (R&D system Co. Ltd., Minneapolis,
MN).
2.10. Statistical analysis
All the studies for statistical evaluation were performed in trip-
licate in each experiment and repeated at least three times.
Mean ± S.D. values were calculated and differences were evaluated
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Fig. 1. Regulation of adhesion, migration and movement of SCLC cells by modu-
lating CXCR4 functions. (A) SBC-5 cells were stimulated with CXCL12 (100 ng/ml)
and/or TF14016 (100 nmol/l) for 2 h, then attached cells were quantitated using
MST method. Relative fold increase values of adhesion to untreated cells are shown.
Columns, the mean values from three independent experiments in triplicate; bars,
S.D. ⁄, P < 0.05 and ⁄⁄, P < 0.003. (B) Migration of SBC-5 cells was evaluated by a
trans-well assay. Cells plated in upper chambers were incubated in membrane-
separated 0.5 lg/ml ﬁbronectin-containing media in lower chambers with or
without CXCL12 (100 ng/ml) and/or TF14016 (100 nmol/l) for 20 h at 37 C. The
number of migrating cells was photographed by HS BZ-9000 microscope and
counted by BZ-II Analyzer. Relative ratios of migrated cells to untreated control are
shown with photographs for each representative well. Columns, the mean values
from three independent experiments in triplicate; bars, S.D. ⁄, P < 0.05. (C) SBC-5
cells were allowed to adhere for 2 h, then recorded every 3 min for another 4 h by
TLVM in the presence or absence of CXCL12 (100 ng/ml) and/or TF14016 (100 nmol/
l). Movement of randomly selected 10 cells is presented as the distance that a cell
traversed every 3 min (lm/3 min). Columns, the mean values (lm/3 min/cell); bars,
S.D. ⁄, P < 0.02 and ⁄⁄, P < 0.01.
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tistically signiﬁcant.
3. Results
3.1. TF14016 suppresses CXCL12-enhanced adhesion, migration, and
movement of SBC-5 cells
Because CXCL12 is shown to enhance adhesion of SCLC cells
to stroma [3–5], the effects of CXCL12 on adhesive potential of
SBC-5 cells were examined. Relative ratio of adherence of
CXCL12-stimulated cells to unstimulated cells was 2.44 ± 0.56
(P < 0.05). TF14016 treatment canceled the effect of CXCL12
to the value of 1.36 ± 0.44 (P < 0.003), but did not inﬂuence the
adherence of SBC-5 cells in the absence of CXCL12 (1.20 ± 0.23)
(Fig. 1A).
Next, we examined the inﬂuence of CXCL12 and TF14016 on
migratory activity of SBC-5 cells. CXCL12 augments migraion of
SBC-5 cells with a fold-increase value of 1.41 ± 0.13 (P < 0.05) com-
pared with unstimulated conditions. TF14016 treatment almost
completely reversed the effect by CXCL12 (1.01 ± 0.11, P < 0.05)
but did not affect the migratory activity in the absence of CXCL12
stimulation (0.98 ± 0.13) (Fig. 1B).
Furthermore, we studied the effect of CXCL12 and TF14016 on
the movement of SBC-5 cells. Cellular movements were recorded
using TLVM and the movement distances of randomly selected 10
cells were calculated and shown in Fig. 1C and Supplementary
Fig. 2. SBC-5 cells became signiﬁcantly more mobile in response
to CXCL12 (1.72 ± 0.59 lm/3 min, P < 0.02) than unstimulated con-
dition (1.10 ± 0.29 lm/3 min). The effect was completely reversed
by the treatment with TF14016 (0.88 ± 0.27 lm/3 min, P < 0.01).
TF14016 alone, without CXCL12 stimulation, did not affect the
motility (1.10 ± 0.25 lm/3 min). These results indicated that
CXCL12/CXCR4 axis positively regulates adhesion and motility of
SBC-5 cells and inhibition of CXCR4 by TF14016 could suppress
these biological functions in vitro.
3.2. TF14016 treatment suppresses metastases of SBC-5 cells in vivo
We further explored in vivo effects of TF14016 on metastatic
potential of SCLC. SBC-5 cells injected into the lateral tail vein of
NK cell-depleted SCID mice formed metastatic pulmonary nodules
with both less number and smaller size in TF14016-treated mice
than vehicle-treated mice (Fig. 2A, a vs. d). The number of
metastatic nodules on the surface of the lung was 9.75 ± 1.26 for
vehicle-treated mice vs. 1.25 ± 0.45 for TF14016-treated mice,
respectively (P < 0.0001) (Fig. 2B).
MVD was higher in vehicle-treated mice (901 ± 122/mm2) than
TF14016-treated mice (525 ± 127/mm2) (P < 0.001) (Fig. 2A, b vs. e,
and 2C). Moreover, in vehicle-treated tumor foci, VEGF was ex-
pressed predominantly in SCLC cells and in several tumor inﬁltrat-
ing host macrophages that were positive by cross-reaction to the
Ab. By contrast, fewer cells were sparsely positive for VEGF in
TF14016-treated tumor foci. The mean percentage of VEGF-posi-
tive cells of all SCLC cells from 10 tumor foci was much higher in
vehicle-treated mice (82.9 ± 5.35%) than in TF14016-treated mice
(8.92 ± 4.25%) (P < 0.0001) (Fig. 2A, c vs. f, and 2D).
With regard to metastases to other major organs, two mice in
vehicle-treated group, but none of TF14016-treated group,
developed 2 and 5 metastatic nodules in the liver, respectively
(data not shown). These ﬁndings suggest that TF14016 not only
prevents SCLC cells from inﬁltrating into the CXCL12-producing
organs but also retards the tumor growth partly through inhibi-
tion of tumor angiogenesis by suppressing VEGF production from
cancer cells.3.3. TF14016 reduces CXCL12/CXCR4-mediated VEGF production from
SBC-5 cells in vitro
The increased VEGF production from SCLC cells in vehicle-trea-
ted mice was thought to be the result of direct induction via
CXCL12/CXCR4 axis or only the result of hypoxia in large tumors.
To clarify this, we measured VEGF concentration in the superna-
tants of SBC-5 cells cultured under normoxic or hypoxic conditions
in the presence or absence of CXCL12 and TF14016. As shown in
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Fig. 2. Suppression of pulmonary metastases by TF14016 treatment is accompanied with reduced vessel density and VEGF expression in tumor foci in mice. SBC-5 cells
(2.5  106) were intravenously inoculated into NK cell-depleted SCID mice after 1 h administration of TF14016 (10 mg/kg i.p.). The mice received daily TF14016 (n = 8) or
vehicle (n = 8) treatment for 12 weeks and sacriﬁced to evaluate treatment efﬁcacy. (A) Representative microscopic images are shown. H&E staining shows more and larger
metastatic pulmonary foci in vehicle-treated group (a) than in TF14016-treated group (d). CD31 staining shows more positive endothelial cells in vehicle-treated group (b)
than in TF14016-treated group (e). Many SCLC cells show intermediate/strong staining intensity for VEGF in vehicle-treated tumor foci (c) in contrast to sparse and weak
positivity in TF14016-treated group (f). (B) TF14016 treatment signiﬁcantly reduced the numbers of metastatic nodules on the lung surface. ⁄, P < 0.0001. (C) MVD in the
metastatic foci assessed by CD31 immunostaining was signiﬁcantly higher in vehicle-treated group than TF14016-treated group. ⁄⁄, P < 0.001. (D) VEGF-positive SCLC cell
percentage of all SCLC cells in tumor nodules was signiﬁcantly higher in vehicle-treated group than in TF14016-treated group. ⁄⁄⁄, P < 0.0001. Data are presented as the mean
(columns) ± S.D. (bars).
3642 Y. Otani et al. / FEBS Letters 586 (2012) 3639–3644Fig. 3, under normoxic condition, CXCL12 induced VEGF production
(389.8 ± 12.4 pg/ml, P < 0.01) compared with unstimulated state
(362.5 ± 5.1 pg/ml) and TF14016 inhibited the effect (298.8 ±
7.2 pg/ml, P < 0.01). Hypoxia enhanced VEGF production more
strongly (485.8 ± 43.2 pg/ml, P < 0.01) and CXCL12 had an additive
effect (569.2 ± 26.3 pg/ml, P < 0.02), which were signiﬁcantly sup-
pressed by TF14016 (449.8 ± 16.9 pg/ml, P < 0.01), respectively.
CXCL12 concentrations were below the measurable threshold level
in all the conditions without CXCL12 stimulation (data not shown).
These observations indicate that not only CXCL12/CXCR4 could di-
rectly induce VEGF production but also hypoxia might upregulate
endogenous CXCL12, as one of the hypoxia-inducible factors, that
activate CXCR4 in an autocrine mechanism.
4. Discussion
The main cause for the extreme aggressiveness and ultimately
poor outcome of SCLC is believed to be widespread microscopicmetastases early in its clinical course. Therefore, development of
a new anti-metastatic treatment strategy is desired. Since expres-
sion of CXCR4 in tumor cells has been shown to be crucial for their
organ-speciﬁc metastasis in a variety of malignancies including
SCLC, CXCR4 could be an attractive therapeutic target.
A couple of anti-CXCR4 strategies such as neutralizing antibod-
ies [6], siRNAs [7], and small molecule inhibitors [8–10], have been
studied in many malignancies, but not in SCLC to date. We here
demonstrated that antagonizing CXCR4 by TF14016 markedly sup-
pressed the formation of metastatic pulmonary nodules of intrave-
nously injected SCLC cells in mice (Fig. 2A and B). This is the ﬁrst
presentation of the in vivo anti-metastatic effect of blocking CXCR4
in SCLC. These ﬁndings reproducibly show the signiﬁcance and uni-
versality of CXCR4 in organ-speciﬁc spread of malignant cells and
the possibility of CXCR4 as therapeutic target for metastasis also
in SCLC.
How does CXCR4 participate in the formation of metastatic foci,
then? Suppression of pulmonary metastases by these inhibitors is
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Fig. 3. TF14016 reduces CXCL12/CXCR4-mediated VEGF production from SCLC
cells. SBC-5 cells (3  104) were incubated in 10% FBS-containing media with or
without CXCL12 (100 ng/ml) and/or TF14016 (100 nmol/l) for 24 h either in
normoxic or hypoxic (1% O2) condition. Conditioned supernatants were collected
and subjected to ELISA to measure the concentrations of VEGF. Column, the mean
value from three independent experiments in triplicate; bar, S.D. ⁄, P < 0.01 and ⁄⁄,
P < 0.02.
Y. Otani et al. / FEBS Letters 586 (2012) 3639–3644 3643understood as the total results of multistep inhibition of CXCR4:
step 1; prevention of tumor cells from inﬁltrating into the lung
immediately after they ﬂow into systemic circulation, step 2; inhi-
bition of consecutive adhesion and migration of inﬁltrated cancer
cells to lung stroma, step 3; direct suppression of tumor growth
after homing to lung stroma, and step 4; indirect suppression of tu-
mor growth via inhibition of tumor angiogenesis.
Interestingly, in the experiment using CTCE-9908, reduction of
pulmonary metastases of osteosarcoma cells was reproducible
only when these cells were pre-treated with the inhibitor before
inoculation. Pre-treatment with CTCE-9908 made these cells un-
able to inﬁltrate into the lung [10]. In another experiment, breast
cancer cells developed less metastatic pulmonary nodules when
they were transfected with CXCR4-targeting siRNA before inocula-
tion compared with mice treated with siRNA after intravenous
injection of untransfected cells [7]. These observations suggest that
CXCR4 inhibitors mainly act at the very earliest phase of metasta-
sis, which is relevant to the inﬁltration of tumor cells into predes-
tinate organs (step 1).
Moreover, CXCL12-enhanced cellular attachment and move-
ment of SCLC cells has been shown to be accompanied with Akt
and/or extracellular signal-regulated kinase (ERK) 1/2 activation
[3,4]. In our experiment, ERK 1/2 but not Akt was further phos-
phorylated upon CXCL12 stimulation within 15 min and TF14016
protected this activation. (Supplementary Fig. 3). These ﬁndings
imply that CXCR4 inhibitors could suppress adhesion and motility
of cancer cells on the stroma of target organs, the consecutive
important step toward the development of metastatic foci (step 2).
In the next step, tumor cells need to proliferate to develop met-
astatic nodules after homing to target organs. In our present study,
proliferation of SBC-5 cells was not affected by CXCL12 and/or
TF14016 (Supplementary Fig. 4). In contrast, another study showed
that none of the mice inoculated with CXCR4 knocked-down breast
cancer cells could develop tumors in their mammary fat-pads [13].
These ﬁndings could explain that CXCL12/CXCR4 axis might di-
rectly promote tumor growth and inhibition of CXCR4 can antago-
nize this effect in several types of malignancies (step 3), the
contribution of which is variable among cell types.
Furthermore, blockade of CXCR4 has been shown to have anti-
angiogenic effects on tumor neovasculature [8,14]. Consistent with
these reports, MVD in the area of pulmonary metastatic foci was
far lower in TF14016-treated mice than in the vehicle-treated mice(Fig. 2A and C). We found that SBC-5 cells in metastatic foci pro-
duced more considerable amount of VEGF in vehicle-treated mice
than TF14016-treated mice (Fig. 2A and D). Generally, the larger
tumors grow, the more cancer cells fall into hypoxic state. Hypox-
ia-inducible factor-mediated mechanism is probably the major
pathway for upregulation of VEGF expression. As shown in Fig. 3,
hypoxia induced VEGF production in SBC-5 cells. Moreover,
CXCL12 directly upregulated VEGF expression even in normoxic
condition and this effect was suppressed by TF14016. These ﬁnd-
ings support that the anti-angiogenic mechanisms by inhibiting
CXCR4 contributed to suppress the growth of metastasized SCLC
cells (step 4).
Collectively, we demonstrated that antagonizing CXCR4
functions by a small peptidic inhibitor TF14016 could almost com-
pletely protect SCLC cells from developing organ-speciﬁc metasta-
ses. Blockade of CXCR4 is thought to inhibit all the steps necessary
for the development of metastatic foci, not only tumor cell inﬁltra-
tion into CXCL12-producing predestinate organs but also adhesion,
migration, invasion and tumor angiogenesis. Therefore, targeting
CXCR4 is a promising strategy for the suppression of proliferation
and metastasis of SCLC. Furthermore, blockade of CXCR4 has been
shown to cancel the cell adhesion-mediated drug resistance in
SCLC which is strengthened by CXCL12-induced cooperation of
CXCR4 with integrins [5]. Combination of CXCR4 antagonists with
cytotoxic chemotherapy looks more attractive providing additional
advantage to overcome chemoresistance in SCLC. Some of CXCR4
inhibitors are currently under investigation in clinical trials in
hematologic malignancies such as multiple myeloma, lymphoma,
and leukemia [15,16]. Clinical trials in solid tumors including SCLC
are urgently desired to be launched.
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